What is CJC-1295 + Ipamorelin? A GH Secretagogue Breakdown
Compound Spotlight
CJC-1295 with Ipamorelin is the most common pairing in growth hormone secretagogue research, and it rests on a real physiological principle rather than a marketing one. It is also the compound in this catalog most affected by a naming problem: what is sold as “CJC-1295” is frequently not CJC-1295 at all.
Quick summary
- Two compounds acting on two separate receptors: CJC-1295 at the GHRH receptor, Ipamorelin at the ghrelin receptor (GHS-R1a).
- Because the receptors are distinct and non-competing, the combined GH pulse is larger than either produces alone.
- Naming trap: “CJC-1295” with DAC has a half-life of days; “CJC-1295 without DAC” is Mod GRF (1-29), with a half-life around 30 minutes. These are functionally different compounds.
- Ipamorelin’s distinguishing feature is selectivity — minimal effect on cortisol and prolactin, unlike older GHRPs.
- Both preserve pulsatile GH release, which is the main physiological argument for secretagogues over administered GH.
- Neither is approved. Human data is limited to early-phase pharmacology, not outcome trials.
Two receptors, one output
Growth hormone release from the pituitary is governed by two opposing hypothalamic signals — GHRH, which stimulates release, and somatostatin, which inhibits it — plus a third input, ghrelin, acting at its own receptor.
CJC-1295 is a GHRH analog: it engages the GHRH receptor, the pituitary’s primary “release” input. Ipamorelin is a ghrelin receptor agonist: it engages GHS-R1a, which both stimulates release through a separate pathway and suppresses somatostatin tone.
The combination is therefore pushing the accelerator while easing off the brake, through two independent receptor systems that do not compete for the same binding site. This is a genuine physiological rationale, well described in the endocrinology literature, and it is the reason the pairing is standard rather than arbitrary.
The DAC problem
This is the single most important practical point about CJC-1295, and it is routinely muddled in commercial listings.
CJC-1295 proper carries a Drug Affinity Complex — a maleimide group that binds covalently to serum albumin after administration. Albumin binding protects the peptide from clearance and extends its half-life to roughly a week, producing a sustained elevation in GH and IGF-1.
“CJC-1295 without DAC” is a different molecule: modified GRF (1-29), a tetrasubstituted GHRH fragment with amino acid substitutions that resist enzymatic degradation but no albumin-binding group. Its half-life is on the order of 30 minutes.
The functional consequence is substantial. The DAC version produces a prolonged elevation of GH signalling — sometimes called a “bleed” — which flattens the natural pulsatile pattern. The non-DAC version produces a short, sharp pulse that more closely resembles physiological release. Researchers who care about preserving pulsatility generally prefer the short-acting form, and pairing it with Ipamorelin, which is also short-acting, is what makes the classic combination pulse-shaped rather than continuous.
Anyone reading research or product listings should confirm which molecule is actually being discussed. The names are used interchangeably far more often than the pharmacology permits.
Why Ipamorelin specifically
Ipamorelin is a pentapeptide and a member of the growth hormone releasing peptide (GHRP) family, but it was developed for selectivity that earlier members lacked.
GHRP-6 and GHRP-2 stimulate GH release effectively but also raise cortisol, prolactin, and ACTH to varying degrees, and GHRP-6 in particular produces marked appetite stimulation via ghrelin signaling. Ipamorelin was characterized as producing GH release with minimal effect on those other axes, which is precisely why it became the default partner compound: it isolates the intended output rather than dragging several endocrine systems along with it.
Pulsatility, and why it is the point
Endogenous GH is not released continuously. It comes in discrete pulses, largely during slow-wave sleep, with low levels between them. There is good evidence that the pulsatile pattern itself carries biological information — target tissues respond differently to pulses than to sustained exposure, and receptor sensitivity is maintained partly by the troughs between peaks.
This is the central argument for secretagogues over exogenous growth hormone. Administered GH creates sustained elevation that overrides the natural rhythm entirely; secretagogues amplify a pattern the body is already generating, and remain subject to negative feedback — rising IGF-1 and somatostatin still restrain the pituitary. That feedback provides a ceiling that direct GH administration does not have.
What the evidence supports
That these compounds increase GH and IGF-1 in humans is well established — this is measurable pharmacology, demonstrated in early-phase studies. CJC-1295 was developed by ConjuChem and taken into human pharmacokinetic work; Ipamorelin was developed by Novo Nordisk and studied in early clinical settings.
What is not established is downstream clinical outcome. Neither compound completed development to approval, and there are no large trials demonstrating that the GH elevation produced translates into meaningful long-term functional benefits. The gap between “raises a hormone” and “improves an outcome” is the same gap that appears throughout this catalog, and it has not been closed here either. Both are also prohibited in competitive sport under WADA rules.
Frequently asked questions
What is the practical difference between CJC-1295 with and without DAC?
Half-life. With DAC it binds albumin and persists for days, producing sustained GH elevation. Without DAC (Mod GRF 1-29) it lasts roughly 30 minutes, producing a discrete pulse. They behave as different compounds.
Why pair two compounds instead of using one?
They act on separate, non-competing receptors — GHRH and ghrelin — and the ghrelin pathway also reduces somatostatin inhibition. The combined effect on GH release is greater than either alone.
How is this different from taking growth hormone?
Secretagogues stimulate the pituitary’s own release and remain subject to negative feedback, preserving pulsatility. Exogenous GH bypasses the pituitary entirely and produces sustained levels without that regulatory ceiling.
How do I know what is actually in the vial?
Every lot we sell has a published Certificate of Analysis from an independent, third-party lab confirming identity and purity. Given the DAC/non-DAC ambiguity in this category, identity confirmation is particularly worth checking.
References
- Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45–53.
View the CJC-1295 + Ipamorelin product listing →
Read our growth hormone secretagogue guide →
Look up your lot Certificate of Analysis →
For laboratory and research use only. Not for human consumption. Neither compound is approved by any regulatory authority, and both are prohibited in competitive sport under WADA rules. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.
Related research compounds
Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:
For laboratory research use only. Not for human consumption.
